FDA Approves New Radioligand Therapy and Diagnostic for mCRPC FDA Approves New Radioligand Therapy and Diagnostic for mCRPC

The agency has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for treatment and gallium Ga 68 gozetotide (Locametz) as a diagnostic for use with PET imaging.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news